Renal cell carcinoma (RCC) accounts for approximately 90% of all renal malignancies. Sunitinib is the gold standard for the treatment of advanced RCC, but several patients have an inherent resistance to antiangiogenic drugs . To facilitate therapeutic decisions in these patients, researchers have conducted a clinical trial to compare a combination of avelumab plus axitinib versus sunitinib in patients with advanced RCC .
The study results are described in Table 1 and progression-free survival rate is represented in Figure 1. Table 1: Results of Clinical trial Parameters (patients with PD-L1–positive tumors) Avelumab plus axitinib sunitinib Sample size (n=873) 434 439 Progression-free survival 13.8 months 7.2 months Median follow-up 9.9 months 8.4 months Deaths 13.7% 15.2% Confirmed objective response rate 55.2% 25.5% Confirmed complete response rates 4.4% 2.1% Overall Adverse events…
